Our data indicated that GILncSig is able to identify a sub-population of pancreatic cancer patients who might be at a higher mortality rate and thus deserve a more radical treatment regimen that could otherwise go unnoticed due to their KRAS wild type status. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.